Search

Dr Amit Patel

Haematology, Intensive care medicine

  • Fee assured
Overview
COVID-19

You'll need to contact this healthcare professional to check their availability

Specialises in

  • Haemato-oncology

About me

Dr Amit Patel is the first person in the UK qualified in stem cell transplantation/cellular therapy and intensive care medicine.

He graduated in Medicine from Imperial College London. After developing gene editing expertise at the Medical Research Council (MRC) London Research Institute he was awarded a PhD in Clinical Science and Molecular Genetics. He completed National Institute for Health Research (NIHR) and Academy of Medical Sciences funded postdoctoral research at the Institute of Cancer Research, and clinical academic training in London, mainly at the Royal Marsden and Hammersmith Hospitals. He was a Consultant Haematologist at the Clatterbridge Cancer Centre in Liverpool, and an Honorary Senior Clinical Lecturer at the University of Liverpool, before commencing his current Consultant role at The Christie NHS Foundation Trust.

He is currently the Lead Haematologist for the immune effector cell (IEC) therapy service that includes chimeric antigen receptor T cell (CAR-T) therapy. He is also the Lead Clinician for Haematology and Transplant Research at The Christie NHS Foundation Trust. Dr Patel is the current and previous UK Chief Investigator (CI) for national and international clinical trials, as similarly principal investigator (PI) for clinical trials. His significant research contribution has been nationally recognised, and in 2019 he won the Royal College of Physicians (RCP) NIHR Clinical Research Network (CRN) Joint Research Award.

During his tenure as a Consultant in Liverpool, as Programme Director of Clatterbridge’s Stem Cell Transplantation and Cellular Therapy Unit, Dr Patel achieved step change improvement in patient survival outcomes to amongst the best in the UK. Dr Patel was also the Lead Clinician for the Leukaemia Unit, where he similarly improved patient outcomes and access to innovative and emerging treatments for patients with ALL and AML. In addition, Dr Patel was the Lead Clinician for Haematology-Oncology Clinical Trials, both departmental within the NHS Trust, and regionally for the NIHR CRN North West Coast (NWC). His leadership achievements were recognised by the NWC Research and Innovation Awards 2020.

Dr Patel has developed regional patient pathways, as Chair of the Haematology Clinical Quality Group (CQG), within the Cheshire and Merseyside Cancer Alliance. This has reduced variation in both patient access and care. He is also President of the Pathology Section of the Royal Society of Medicine.

He has delivered invited lectures at international and national meetings and conferences, published in high impact journals, contributed to patient support groups and charities including as a trustee, and provided clinical expertise and leadership to new and emerging therapies to accelerate patient access, including through NICE.

Areas of interest

Treatments: CAR-T cell therapy, immune effector cell (IEC) therapy, stem cell transplantation, blood and marrow transplantation, haematopoietic stem cell transplantation (HSCT), immunotherapy. Diseases: leukaemia, acute lymphoblastic leukaemia (ALL), acute myeloid leukaemia (AML), myelodysplastic syndrome (MDS) / chronic myelomonocytic leukaemia (CMML), chronic myeloid leukaemia (CML), lymphoma, myeloma, bone marrow failure, graft versus host disease (GvHD)

Medical secretaries

About me
My qualifications & training
Consultant's practices
Information for healthcare professionals

Information for healthcare professionals (Bupa patients only, last 12 months)

Procedures completed

  • X0004

    Clinical supervision and planning for delivery of chemotherapy cycle 1 - 28 days - (1-5)

    The Christie Clinic (1-5)

Report this page Edit details Print page

The information contained on Finder is submitted by consultants, therapists and healthcare services, and is declared by these third parties to be correct and compliant with the standards and codes of conduct specified by their relevant regulatory body. Bupa cannot guarantee the accuracy of all of the information provided.

You can find out more about the information on Finder and our website terms of use.